Zentalis Pharmaceuticals (NASDAQ:ZNTL) Upgraded at Wedbush
Wedbush upgraded shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) from an underperform rating to a neutral rating in a report issued on Monday, Marketbeat.com reports. The firm currently has $4.00 price target on the stock. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q3 2024 earnings at ($0.86) EPS, Q4 2024 earnings at ($0.87) EPS, […]
More Stories
Wells Fargo & Company Issues Pessimistic Forecast for Kezar Life Sciences (NASDAQ:KZR) Stock Price
Kezar Life Sciences (NASDAQ:KZR – Free Report) had its price target lowered by Wells Fargo & Company from $20.00 to...
Forian (NASDAQ:FORA) Receives “Buy” Rating from Roth Mkm
Roth Mkm reiterated their buy rating on shares of Forian (NASDAQ:FORA – Free Report) in a research report released on...
China Feihe Limited (OTCMKTS:CHFLF) Short Interest Update
China Feihe Limited (OTCMKTS:CHFLF – Get Free Report) was the recipient of a significant increase in short interest in the...
Short Interest in Clariant AG (OTCMKTS:CLZNY) Drops By 50.0%
Clariant AG (OTCMKTS:CLZNY – Get Free Report) was the recipient of a significant decrease in short interest in October. As...
Croda International Plc (OTCMKTS:COIHY) Sees Large Increase in Short Interest
Croda International Plc (OTCMKTS:COIHY – Get Free Report) was the recipient of a significant increase in short interest in October....
KCM Investment Advisors LLC Sells 461 Shares of Tesla, Inc. (NASDAQ:TSLA)
KCM Investment Advisors LLC reduced its stake in shares of Tesla, Inc. (NASDAQ:TSLA – Free Report) by 2.4% during the...